### Supplementary Table 1. SARS-CoV-2 monoclonal antibodies authorized for COVID-19 treatment in children and adolescents

|                     | Bamlanivimab/etesevimab | Casirivimab/imdevimab | Sotrovimab |
|---------------------|--------------------------|------------------------|------------|
| Minimum age and weight                       | &gt;1 kg &nbsp; Available for infants and young children &lt;12 years | &ge;12 years &gt;40 kg | &ge;12 years &gt;40 kg |
| **Dosage**                         | 1 to 12 kg: 12 mg/kg and 24 mg/kg | >12 to 20 kg: 175 mg/350 mg | 600 mg/600 mg | 500 mg |
|                                     | &gt;20 to 40 kg: 350 mg/700 mg | ≥40 kg: 700 mg/1,400 mg | 600 mg/600 mg | 500 mg |
| Route of administration               | IV                        | IV preferred: SC alternative if IV not feasible or available | IV         |
| **Timing of administration**          | Provide ASAP after positive SARS-CoV-2 test and within 10 days of symptom onset | Nonhospitalized patient, and | Nonhospitalized patient, and |
| **EUA criteria**                     | Laboratory-confirmed SARS-CoV-2 infection, and | Laboratory-confirmed SARS-CoV-2 infection, and | Laboratory-confirmed SARS-CoV-2 infection, and |
|                                     | Mild to moderate COVID-19, and | Mild to moderate COVID-19, and | Mild to moderate COVID-19, and |
|                                     | Within 10 days of symptom onset, and | Within 10 days of symptom onset, and | Within 10 days of symptom onset, and |
|                                     | High risk for progressing to severe COVID-19 and/or hospitalization | High risk for progressing to severe COVID-19 and/or hospitalization | High risk for progressing to severe COVID-19 and/or hospitalization |
| **High-risk criteria**               | Body mass index ≥ 85th percentile for age and gender | Immunosuppressive disease or receipt of immunosuppressive therapies | Chronic kidney disease |
|                                     | Neurodevelopmental disorders (e.g., cerebral palsy, trisomy 21) | A medical-related technological dependence that is not related to COVID-19 (e.g., tracheostomy, positive pressure ventilation, gastrostomy) | Chronic kidney disease |
|                                     | Sickle cell disease | Sickle cell disease | Chronic kidney disease |
|                                     | Congenital or acquired heart disease | Congenital or acquired heart disease | Chronic kidney disease |
|                                     | Chronic lung disease (e.g., interstitial lung disease, tuberculosis); asthma or other chronic respiratory disease that requires daily medication for control | Chronic lung disease (e.g., interstitial lung disease, tuberculosis); asthma or other chronic respiratory disease that requires daily medication for control | Chronic kidney disease |
|                                     | Diabetes | Diabetes | Chronic kidney disease |
|                                     | Chronic liver disease (e.g., cirrhosis, autoimmune hepatitis) | Chronic liver disease (e.g., cirrhosis, autoimmune hepatitis) | Chronic kidney disease |
|                                     | Pregnancy; or | Pregnancy; or | Chronic kidney disease |
|                                     | Age &lt;1 year | Age &lt;1 year | Chronic kidney disease |

SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; COVID-19, coronavirus disease 2019; IV, intravenous; SC, subcutaneous; ASAP, as soon as possible; EUA, emergency use approval.